Tibet Pharmaceuticals (TBET)
Tibet Pharmaceuticals Revenues: 8.583M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
TBET Revenues Rankings
| Overall | 11th percentile | 3900 of 4431 |
| Sector | 29th percentile | 330 of 471 in Healthcare |
| Industry | 8th percentile | 11 of 12 in Drugs - Generic |
TBET Revenues Range, Past 5 Years
| Minimum | 8.237M | Mar 2011 |
| Maximum | 8.746M | Jun 2011 |
| Average | 8.522M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these TBET related companies
TBET News
Rosen Law Firm Files Class Action Against Tibet Pharmaceuticals, Inc. – TBET
May 26, 9:02AM Business Wire
May 26, 9:02AM Business Wire
@RGT It is on their website. $TBET. Something they are working on and going toward FDA approval.
about 33 days ago by mmritas
about 33 days ago by mmritas
$TBET is doing some research. If it pans out, it will be back in Nasd again. But it is a waiting game.
about 34 days ago by mmritas
about 34 days ago by mmritas
@TradeHawk Where did you get that news for $tbet. The lawyer said they are still investigating and nothing is found.
about 37 days ago by mmritas
about 37 days ago by mmritas
$TBET So far nothing is found on wrong doing. Just investigating going on. Nasd reason for halt was NT 10K filing.
about 46 days ago by mmritas
about 46 days ago by mmritas
The Rosen Law Firm Announces Investigation Against Tibet Pharmaceuticals, Inc.
Apr 04, 11:31PM Business Wire
Apr 04, 11:31PM Business Wire
Tibet Pharmaceuticals Signs Letter of Intent to Cooperate With Anhui Taihe Pharmaceutical Group
Jan 31, 4:05PM Benzinga
Jan 31, 4:05PM Benzinga
Tibet Pharmaceuticals Announces Appointment of Sherb & Co., LLP as New Independent Auditor
Oct 18, 9:01AM Benzinga
Oct 18, 9:01AM Benzinga
Tibet Pharmaceuticals Announces Appointment of Sherb & Co., LLP as New Independent Auditor
Oct 18, 9:01AM PR Newswire
Oct 18, 9:01AM PR Newswire
Tibet Pharma (TBET) Auditor ACSB Resigns, Says Not Due to Disagreement
Sep 12, 4:17PM Street Insider
Sep 12, 4:17PM Street Insider
Tibet Pharmaceuticals Announces Search for New Auditor Upon Resignation of ACSB
Sep 12, 4:15PM Benzinga
Sep 12, 4:15PM Benzinga
Tibet Pharmaceuticals Announces Availability of Second Quarter 2011 Earnings Call Transcript
Aug 19, 9:31AM PR Newswire
Aug 19, 9:31AM PR Newswire
Tibet Pharmaceuticals Reports Financial Results for Second Quarter Ended June 30, 2011
Aug 15, 3:30PM PR Newswire
Aug 15, 3:30PM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| TBET | 1.29 | +0.00 | +0.00% | 19.16M |
| TBBK | 8.66 | -0.43 | -4.73% | 300.88M |
| TAYC | 14.11 | -0.77 | -5.17% | 423.04M |
| TAXI | 10.33 | +0.01 | +0.10% | 182.87M |
| TAST | 5.85 | -0.25 | -4.10% | 141.28M |
| TAP | 38.33 | -0.12 | -0.31% | 6.087B |
| TAOM | 4.63 | -0.14 | -2.94% | 173.72M |
| TAO | 16.34 | -0.40 | -2.37% | |
| TAN | 17.04 | -0.54 | -3.07% | |
| TAM | 21.17 | -0.57 | -2.62% | 2.182B |
